
Biogen Inc
NASDAQ:BIIB

Intrinsic Value
The intrinsic value of one
BIIB
stock under the Base Case scenario is
174.28
USD.
Compared to the current market price of 127.04 USD,
Biogen Inc
is
Undervalued by 27%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Biogen Inc
Fundamental Analysis

Biogen’s ambitious bet on Alzheimer’s treatments, particularly its contentious drug Aduhelm, has experienced regulatory hurdles and sluggish uptake, creating a risk that significant R&D investments will fail to yield commensurate returns and weigh on margins.
If Biogen’s Alzheimer’s portfolio, including any follow-on therapies or next-generation products, achieves broader Medicare reimbursement and stronger clinical data, the company could capture a significant share of a vast, unmet market for neurodegenerative treatments.

Revenue & Expenses Breakdown
Biogen Inc
Balance Sheet Decomposition
Biogen Inc
Current Assets | 7.6B |
Cash & Short-Term Investments | 2.6B |
Receivables | 2B |
Other Current Assets | 3B |
Non-Current Assets | 20.4B |
Long-Term Investments | 559.1m |
PP&E | 3.5B |
Intangibles | 16.1B |
Other Non-Current Assets | 307.5m |
Free Cash Flow Analysis
Biogen Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Biogen Inc
Revenue
|
9.8B
USD
|
Cost of Revenue
|
-2.4B
USD
|
Gross Profit
|
7.4B
USD
|
Operating Expenses
|
-4.8B
USD
|
Operating Income
|
2.6B
USD
|
Other Expenses
|
-1.1B
USD
|
Net Income
|
1.5B
USD
|
BIIB Profitability Score
Profitability Due Diligence
Biogen Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Score
Biogen Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
BIIB Solvency Score
Solvency Due Diligence
Biogen Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Score
Biogen Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIIB Price Targets Summary
Biogen Inc
According to Wall Street analysts, the average 1-year price target for
BIIB
is 173.34 USD
with a low forecast of 116.15 USD and a high forecast of 273 USD.
Dividends
Current shareholder yield for BIIB is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BIIB
stock under the Base Case scenario is
174.28
USD.
Compared to the current market price of 127.04 USD,
Biogen Inc
is
Undervalued by 27%.